A recent study published in the Journal of Affective Disorders suggests that a single dose of psilocybin may offer hope for U ...

Analyst Vikram Purohit of Morgan Stanley maintained a Buy rating on COMPASS Pathways (CMPS – Research Report), with a price target of ...

Psychedelic mushrooms, containing the active ingredient psilocybin, have shown remarkable potential in treating various mental health conditions, including treatment-resistant depression. Leading ...

State lawmakers are considering a bill that would legalize production and use of psilocybin as a mental health treatment in ...

Compass Pathways is advancing pivotal trials to test psilocybin's impact on treatment-resistant depression. See why I rate ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Esketamine nasal spray (Spravato) monotherapy ...

A groundbreaking study reveals that a portable electrostimulation device could revolutionize the treatment of severe ...

Esketamine for TRD demonstrated efficacy in reducing depressive symptoms and did not significantly differ based on TMS treatment history.

Compass Pathways plc has exciting developments in treating treatment-resistant depression with the innovative COMP360. Click ...

With its clinical trials at a pivotal stage, Compass Pathways is burning more cash, but reported a slightly ...

In such cases, patients may be prescribed neuromodulation therapy, which modulates brain activity in order to reduce ...

In another delay for the psychedelic treatment space, Compass Pathways announced adjusted timelines for two Phase III trials ...